TY - JOUR
T1 - Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation
AU - Sidiqi, M. Hasib
AU - Aljama, Mohammed A.
AU - Muchtar, Eli
AU - Buadi, Francis K.
AU - Warsame, Rahma
AU - Lacy, Martha Q.
AU - Dispenzieri, Angela
AU - Dingli, David
AU - Leung, Nelson
AU - Gonsalves, Wilson I.
AU - Kapoor, Prashant
AU - Kourelis, Taxiarchis V.
AU - Hogan, William J.
AU - Wolf, Robert C.
AU - Kumar, Shaji K.
AU - Gertz, Morie A.
N1 - Funding Information:
Conflict of interest MAG received consultancy from Millenium and honoraria from Celgene, Millenium, Onyx, Novartis, SmithKline, Prothena, Ionis, and Amgen. SKK received consultancy from Celgene, Millennium, Onyx, Janssen, and BMS and research funding from Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS. MQL received research funding from Celgene. DD received research funding from Karyopharm Therapeutics, and Millenium Pharmaceuticals. PK received research funding from Takeda, Celgene, and Amgen. AD received research funding from Celgene, Millennium, Pfizer, and Janssen and travel grant from Pfizer. The remaining authors declare that they have no conflict of interest.
Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - High-dose melphalan is the standard conditioning regimen for patients with AL amyloidosis receiving autologous stem cell transplantation. Conventional formulations require propylene glycol (PG) as a co-solvent and melphalan has limited solubility and chemical stability after reconstitution, with potential risks for propylene glycol-related complications. Captisol-stabilized propylene glycol-free (PG-free) melphalan has been developed with improved solubility and chemical stability. We compared a cohort of patients with AL amyloidosis receiving PG melphalan (n = 96) to those receiving PG-free melphalan (n = 48) as conditioning for autologous stem cell transplantation. Median time to neutrophil and platelet engraftment was the same; 14 days PG melphalan vs 14 days PG-free melphalan, p = 0.73 and 16 days PG melphalan vs 16 days PG-free melphalan, p = 0.52, respectively. Hospitalization rate was similar in both cohorts, 68% PG melphalan vs 58% PG-free melphalan, p = 0.27. All-cause mortality at 100 days was not statistically significant, 3% PG melphalan vs 2% PG-free melphalan, p > 0.99. Overall response rate (ORR) and rates of complete response (CR) were similar (ORR 93% PG melphalan vs 94% PG-free melphalan, p > 0.99 and CR 39% PG melphalan vs 32% PG-free melphalan, p = 0.46). PG-free melphalan showed a comparable safety and efficacy profile to PG melphalan in patients with AL amyloidosis receiving stem cell transplantation.
AB - High-dose melphalan is the standard conditioning regimen for patients with AL amyloidosis receiving autologous stem cell transplantation. Conventional formulations require propylene glycol (PG) as a co-solvent and melphalan has limited solubility and chemical stability after reconstitution, with potential risks for propylene glycol-related complications. Captisol-stabilized propylene glycol-free (PG-free) melphalan has been developed with improved solubility and chemical stability. We compared a cohort of patients with AL amyloidosis receiving PG melphalan (n = 96) to those receiving PG-free melphalan (n = 48) as conditioning for autologous stem cell transplantation. Median time to neutrophil and platelet engraftment was the same; 14 days PG melphalan vs 14 days PG-free melphalan, p = 0.73 and 16 days PG melphalan vs 16 days PG-free melphalan, p = 0.52, respectively. Hospitalization rate was similar in both cohorts, 68% PG melphalan vs 58% PG-free melphalan, p = 0.27. All-cause mortality at 100 days was not statistically significant, 3% PG melphalan vs 2% PG-free melphalan, p > 0.99. Overall response rate (ORR) and rates of complete response (CR) were similar (ORR 93% PG melphalan vs 94% PG-free melphalan, p > 0.99 and CR 39% PG melphalan vs 32% PG-free melphalan, p = 0.46). PG-free melphalan showed a comparable safety and efficacy profile to PG melphalan in patients with AL amyloidosis receiving stem cell transplantation.
UR - http://www.scopus.com/inward/record.url?scp=85055983597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055983597&partnerID=8YFLogxK
U2 - 10.1038/s41409-018-0388-x
DO - 10.1038/s41409-018-0388-x
M3 - Article
C2 - 30390060
AN - SCOPUS:85055983597
SN - 0268-3369
VL - 54
SP - 1077
EP - 1081
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 7
ER -